AU2013368843B2 - Novel quinolone derivatives - Google Patents

Novel quinolone derivatives Download PDF

Info

Publication number
AU2013368843B2
AU2013368843B2 AU2013368843A AU2013368843A AU2013368843B2 AU 2013368843 B2 AU2013368843 B2 AU 2013368843B2 AU 2013368843 A AU2013368843 A AU 2013368843A AU 2013368843 A AU2013368843 A AU 2013368843A AU 2013368843 B2 AU2013368843 B2 AU 2013368843B2
Authority
AU
Australia
Prior art keywords
oho0
hydroxy
oxo
carboxamido
acetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013368843A
Other languages
English (en)
Other versions
AU2013368843A1 (en
Inventor
Ranjit C. Desai
Vrajesh PANDYA
Pankaj R. Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Zydus Lifesciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54148255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013368843(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zydus Lifesciences Ltd filed Critical Zydus Lifesciences Ltd
Publication of AU2013368843A1 publication Critical patent/AU2013368843A1/en
Application granted granted Critical
Publication of AU2013368843B2 publication Critical patent/AU2013368843B2/en
Assigned to ZYDUS LIFESCIENCES LIMITED reassignment ZYDUS LIFESCIENCES LIMITED Request to Amend Deed and Register Assignors: CADILA HEALTHCARE LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
AU2013368843A 2012-12-24 2013-12-23 Novel quinolone derivatives Active AU2013368843B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3600/MUM/2012 2012-12-24
IN3600MU2012 2012-12-24
PCT/IN2013/000796 WO2014102818A1 (en) 2012-12-24 2013-12-23 Novel quinolone derivatives

Publications (2)

Publication Number Publication Date
AU2013368843A1 AU2013368843A1 (en) 2015-06-18
AU2013368843B2 true AU2013368843B2 (en) 2016-02-25

Family

ID=54148255

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013368843A Active AU2013368843B2 (en) 2012-12-24 2013-12-23 Novel quinolone derivatives

Country Status (26)

Country Link
US (1) US9394300B2 (enExample)
EP (1) EP2935221B1 (enExample)
JP (1) JP6026013B2 (enExample)
KR (1) KR101733901B1 (enExample)
CN (1) CN104903295B (enExample)
AP (1) AP2015008502A0 (enExample)
AR (1) AR094300A1 (enExample)
AU (1) AU2013368843B2 (enExample)
BR (1) BR112015014222B1 (enExample)
CA (1) CA2894636C (enExample)
CL (1) CL2015001802A1 (enExample)
EA (1) EA028402B1 (enExample)
ES (1) ES2660288T3 (enExample)
IL (1) IL239109B (enExample)
JO (1) JO3781B1 (enExample)
MA (1) MA38138A1 (enExample)
MX (1) MX373392B (enExample)
MY (1) MY175854A (enExample)
NZ (1) NZ708605A (enExample)
PH (1) PH12015501452B1 (enExample)
SG (1) SG11201504458XA (enExample)
TR (1) TR201802305T4 (enExample)
TW (1) TWI598339B (enExample)
UA (1) UA117122C2 (enExample)
WO (1) WO2014102818A1 (enExample)
ZA (1) ZA201503814B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105384687B (zh) * 2014-09-02 2018-05-01 广东东阳光药业有限公司 喹啉酮类化合物及其在药物中应用
WO2016045125A1 (en) 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CL2015003047A1 (es) * 2015-10-15 2016-06-17 Univ Chile Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN108069957B (zh) * 2016-11-09 2022-11-04 广东东阳光药业有限公司 脯氨酰羟化酶抑制剂及其用途
AU2018264313B2 (en) 2017-05-09 2020-06-04 Kind Pharmaceutical Indolizine derivatives and application thereof in medicine
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
TW202200547A (zh) * 2020-03-13 2022-01-01 印度商卡地拉保健有限公司 喹啉酮化合物的新穎鹽類
TW202207930A (zh) * 2020-03-17 2022-03-01 印度商卡地拉保健有限公司 包含ｈｉｆ脯胺醯基羥化酶抑制劑之調和物
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
CN115666539A (zh) * 2020-05-29 2023-01-31 兹杜斯生命科学有限公司 银屑病和皮肤炎性疾病的治疗
EP4157220A1 (en) * 2020-06-01 2023-04-05 Zydus Lifesciences Limited Treatment for the inflammatory bowel disease
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
US20240300899A1 (en) * 2021-03-19 2024-09-12 Zydus Lifesciences Limited A quinolone compound in solid forms and processes for the preparation thereof
WO2022195532A1 (en) * 2021-03-19 2022-09-22 Zydus Lifesciences Ltd. Treatment for sickle cell anaemia
WO2022238745A1 (en) * 2021-05-14 2022-11-17 Zydus Lifesciences Limited Topical pharmaceutical composition of hif prolyl hydroxylase inhibitors
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN113549011B (zh) * 2021-08-10 2023-05-09 广东东阳光药业有限公司 德度司他的共晶或盐及其制备方法和用途
KR20240063900A (ko) * 2021-09-20 2024-05-10 자이두스 라이프사이언시즈 리미티드 데시더스타트 입자 및 이의 조성물
US20250387385A1 (en) * 2022-06-24 2025-12-25 Zydus Lifesciences Limited Treatment for glomerular diseases
EP4565233A1 (en) * 2022-08-01 2025-06-11 Zydus Lifesciences Limited Treatment for aplastic anemia (aa)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007070359A2 (en) * 2005-12-09 2007-06-21 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
WO2007103905A2 (en) * 2006-03-07 2007-09-13 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2008138060A1 (en) * 2007-05-16 2008-11-20 Cowper Norman T System and method for maximising solids concentration of slurry pumped through a pipeline

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
CN102718708A (zh) 2003-06-06 2012-10-10 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
JP4792048B2 (ja) * 2005-03-02 2011-10-12 ファイブロゲン インコーポレイティッド チエノピリジン化合物およびその使用方法
EP3124489B1 (en) * 2006-04-04 2020-07-15 Fibrogen, Inc. Thiazolo-pyridine compounds as hif modulators
WO2007136990A2 (en) * 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JP2009543867A (ja) * 2006-07-17 2009-12-10 メルク エンド カムパニー インコーポレーテッド 抗ｈｉｖ剤としての１−ヒドロキシナフチリジン化合物
WO2008076425A1 (en) * 2006-12-18 2008-06-26 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
JP2010524935A (ja) * 2007-04-18 2010-07-22 メルク・シャープ・エンド・ドーム・コーポレイション 新規１，８−ナフチリジン化合物
ES2442847T3 (es) * 2007-04-18 2014-02-13 Amgen, Inc Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa
WO2008137084A2 (en) * 2007-05-04 2008-11-13 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
ES2389063T3 (es) * 2007-05-04 2012-10-22 Amgen, Inc Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
EP2224926A4 (en) * 2007-11-30 2010-12-01 Glaxosmithkline Llc INHIBITORS OF PROLYL HYDROXYLASES
CA2716798A1 (en) * 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydrofuropyridones
AU2009217541A1 (en) * 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydrothieno pyridines
AU2009217543A1 (en) * 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydro-1H-pyrrolo fused pyridones
US20110098324A1 (en) * 2008-06-25 2011-04-28 Brackley Iii James A Prolyl hydroxylase inhibitors
HRP20140705T1 (hr) 2009-07-17 2014-09-12 Japan Tobacco, Inc. Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
BR112012003701A2 (pt) * 2009-08-20 2019-09-24 Vifor Int Ag "novos antagonistas de quinolina-hepcidina"
US8921389B2 (en) 2011-02-02 2014-12-30 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
WO2013043621A1 (en) 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Substituted pyrimidines
CA2863279A1 (en) * 2012-01-31 2013-08-08 Toyama Chemical Co., Ltd. Heterocyclic compound having anti-hiv activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007070359A2 (en) * 2005-12-09 2007-06-21 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
WO2007103905A2 (en) * 2006-03-07 2007-09-13 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2008138060A1 (en) * 2007-05-16 2008-11-20 Cowper Norman T System and method for maximising solids concentration of slurry pumped through a pipeline

Also Published As

Publication number Publication date
NZ708605A (en) 2016-07-29
ES2660288T3 (es) 2018-03-21
CN104903295B (zh) 2017-09-01
PH12015501452B1 (en) 2018-06-06
JO3781B1 (ar) 2021-01-31
TWI598339B (zh) 2017-09-11
AU2013368843A1 (en) 2015-06-18
IL239109A0 (en) 2015-07-30
ZA201503814B (en) 2016-05-25
MA38138A1 (fr) 2016-11-30
EP2935221B1 (en) 2018-02-07
KR20150085535A (ko) 2015-07-23
BR112015014222B1 (pt) 2022-12-06
CL2015001802A1 (es) 2015-10-02
WO2014102818A1 (en) 2014-07-03
EA201591195A1 (ru) 2015-10-30
US20150299193A1 (en) 2015-10-22
SG11201504458XA (en) 2015-07-30
CA2894636C (en) 2018-04-03
AR094300A1 (es) 2015-07-22
MX2015008233A (es) 2015-09-29
HK1211022A1 (en) 2016-05-13
US9394300B2 (en) 2016-07-19
EA028402B1 (ru) 2017-11-30
JP6026013B2 (ja) 2016-11-16
PH12015501452A1 (en) 2015-09-21
MY175854A (en) 2020-07-14
EP2935221A1 (en) 2015-10-28
IL239109B (en) 2019-07-31
BR112015014222A2 (pt) 2017-07-11
CN104903295A (zh) 2015-09-09
KR101733901B1 (ko) 2017-05-08
MX373392B (es) 2020-04-20
CA2894636A1 (en) 2014-07-03
TW201441196A (zh) 2014-11-01
TR201802305T4 (tr) 2018-03-21
JP2016503052A (ja) 2016-02-01
AP2015008502A0 (en) 2015-06-30
UA117122C2 (uk) 2018-06-25

Similar Documents

Publication Publication Date Title
AU2013368843B2 (en) Novel quinolone derivatives
SG175331A1 (en) Inhibitors of human immunodeficiency virus replication
KR20100108337A (ko) 사람 면역결핍 바이러스 복제의 억제제
AU2008241503A1 (en) Novel 1,8-naphthyridine compounds
JP2011503118A (ja) ヒト免疫不全ウイルスの複製阻害薬
AU2013255437A1 (en) Substituted pyridine compounds as CRAC modulators
KR20200089291A (ko) Acss2 저해제 및 이의 사용 방법
US20100331358A1 (en) Tetrahydrofuropyridones
JP2022532719A (ja) Ａｃｓｓ２阻害剤およびその使用方法
EP2257169A1 (en) Tetrahydrothieno pyridines
KR20190089033A (ko) 항종양제 및 브로모도메인 저해제
US20200131144A1 (en) Amine or (thio)amide containing lxr modulators
US10183949B2 (en) Pyrimidinone derivative having autotaxin-inhibitory activity
US12102626B2 (en) (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer
HK1211022B (en) Quinolone derivatives
OA17332A (en) Novel quinolone derivatives.
US20170240511A1 (en) Substituted pyridine inhibitors of hif prolyl hydroxylase
CN113348167B (zh) 用于治疗癌症的作为TGF-βR1(ALK5)抑制剂的(吡啶-2-基)胺衍生物
TW202409010A (zh) 人類呼吸道融合病毒及人類間質肺炎病毒之抑制劑

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: ZYDUS LIFESCIENCES LIMITED

Free format text: FORMER NAME(S): CADILA HEALTHCARE LIMITED